

Bibliography Report

November 1st 2009 – November 30th 2009

Page 1 of 5

Araten DJ, Sanders K, Anscher D, Hunger S, Ibrahim S. A high frequency of blasts with the PNH phenotype in patients with ALL. *Blood*; (Epub Ahead of print), 2009.
AALL05B1; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9768

Arndt CA, Stoner JA, Hawkins D, Rodeberg D, Hayes-Jordan AA, Paidas CN, Parham D, Teot LA, Wharam MD, Breneman J, Donaldson S, Anderson J, Meyer W. Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. [J Clin Oncol; 27\(31\):5182-5188, 2009](#). PMID: PMC2773476.
D9803; Soft Tissue Sarcoma Committee; Research Paper. COG # 9558

Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo T, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson BE, Hasle H, Harrison CJ, Heerema NA, Kaspers GL, Lezl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Strehl S, Taga T, Tomizawa D, Webb DK, Zemanova Z, Zwaan CM, van den Heuvel-Eibrink MM. Identification of Novel Prognostic Subgroups in Childhood 11Q23/MLL-Rearranged Acute Myeloid Leukemia. *Pediatr Blood Cancer*; 53(5):721, O.034, 2009.
2891, 2941, 2961, 8821; Myeloid Disease Committee; Abstract. COG # 9820

Berman JN, Gerbing R, Sung L, Miller K, Pollard JA, Ho PA, Stirewalt DL, Radich JP, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Gamis A, Franklin J, Alonzo T, Meshinchi S. Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML: A Report From the Children's Oncology Group. *Blood*; (Epub Ahead of print), 2009.
2961, AAML03P1; Myeloid Disease Committee; Abstract. COG # 9815

Bhat R, Malinge S, Gamis A, Sorrell AD, Hilden JM, Paietta E, Tallman M, Ketterling RP, Crispino J. *PMC Journal - In Process*. Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia. [Leukemia; 23\(11\):2159-2160, 2009](#).
A2971; Myeloid Disease Committee; Editorial. COG # 9738

Brown P, Hilden JM, Dreyer Z, Winick N, Salzer WL, Sung L, Zaoutis T, Jones T, Devidas M, de Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger S. Report on excessive induction toxicity in infants with ALL enrolled on COG protocol AALL0631: A Children's Oncology Group study. *Blood*; (Epub Ahead of print), 2009.
AALL0631; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9771

Cairo M, Lynch J, Harrison L, Perkins S, Sanger W, Gross TG, Shiramizu B, Goldman SC. Results of the addition of Rasburicase (RU) and Rituximab (RM) to the FAB/LMB 96 chemotherapy backbone in children and adolescents (C+A) with mature B-NHL: A Children's Oncology Group Report. *Pediatr Blood Cancer*; 53(5):858, #PQ.018, 2009.
ANHL01P1; Non-Hodgkin Lymphoma Committee; Abstract. COG # 9590

Calaminus G, Nagarajan R, Hjorth L, Jenney ME, De Vos P, Wiener A. Quality of Life (QOL) Assessment of Patients Undergoing Therapy for Osteosarcoma in the EUROPEAN AMERICAN OSTEOSARCOMA STUDY (EURAMOS). *Pediatr Blood Cancer*; 53(5):799, PD.035, 2009.
AOST0331; Bone Sarcoma Disease Committee; Abstract. COG # 9809

Carroll AJ, Heerema NA, Devidas M, Bowman P, Wang C, Trigg ME, Camitta BM, Gaynon PS, Winick N, Hunger S, Carroll WL, Schultz KR. Secondary chromosomal abnormalities appear to be less prognostic for children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) treated with intensified imatinib and chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031. *Blood*; (Epub Ahead of print), 2009.
AALL0031; Acute Lymphoblastic Leukemia Disease Committee, Hematopoietic Stem Cell Transplantation Discipline Committee; Abstract. COG # 9731

Bibliography Report

November 1st 2009 – November 30th 2009

Page 2 of 5

Carroll AJ, Heerema NA, Gastier-Foster JM, Astbury C, Pyatt RE, Reshmi SC, Borowitz M, Devidas M, Linda SB, Loh M, Hunger S, Carroll WL. Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) in children mimicking hyperdiploid ALL: A report from the Children's Oncology Group (COG) AALL03B1 Study. *Blood*; (Epub Ahead of print), 2009.

AALL03B1; Acute Lymphoblastic Leukemia Disease Committee, Translational Research Scientific Committee; Abstract. COG # 9752

Castellino SM, Muir A, Shah AJ, Shope S, McMullen KP, Ruble KJ, Barber A, Davidoff AM, Hudson MM. Hepato-Biliary Late Effects in Survivors of Childhood and Adolescent Cancer: A Report from the Children's Oncology Group. [Pediatr Blood Cancer; \(Epub ahead of print\), 2009](#). PMC Journal - In Process.

Cancer Control and Survivorship Scientific Committee; Research Paper. COG # 9513

Chang BH, Willis SG, Stork L, Schultz KR, Hunger S, Carroll WL, Camitta BM, Winick N, Drunker BJ. Mutational analysis of BCR-Abl from subjects with relapsed Ph+ALL treated on the COG protocol AALL0031: A report from the Children's Oncology Group. *Blood*; (Epub Ahead of print), 2009.

AALL0031; Acute Lymphoblastic Leukemia Disease Committee, Hematopoietic Stem Cell Transplantation Discipline Committee; Abstract. COG # 9732

Chen L, Devidas M, Waller J, Hall P, Lukacik M, Camitta BM, Bell B. Hepatotoxicity in standard risk B-cell precursor pediatric acute lymphoblastic leukemia patients treated on Pediatric Oncology Group (POG) protocol 9605. *Blood*; (Epub Ahead of print), 2009.

9605; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9728

Chou AJ, Kleinerman E, Krailo M, Chen Z, Betcher DL, Healey J, Conrad EU, Nieder M, Weiner M, Wells RJ, Womer R, Meyers P. Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly Diagnosed Metastatic Osteosarcoma: a Report from the Children's Oncology Group. [Cancer; 115\(22\):5339-5348, 2009](#). PMID: PMC2783515.

7921; Bone Sarcoma Disease Committee; Research Paper. COG # 9467

Conley SB, Curry JO, Hines M, Baker K, Schmidt K, Zwier KA, Siever BA, Mirisola TM, Burke SL, Thom B, Kline NE. PMC Journal - In Process. Consensus Statements: Ambulatory Pediatric Oncology Nursing Practice. [J Pediatr Oncol Nurs; \(Epub ahead of print\), 2009](#).

Nursing Discipline Committee; Research Paper. COG # 9812

Cooper TM, Alonzo T, Gerbing R, Perentesis J, Whitlock JA, Raetz E, Carroll WL, Gamis A, Razzouk B. AAML0523: A report from the Children's Oncology Group on the safety of clofarabine in combination with cytarabine in pediatric patients with Relapsed Acute Leukemia. *Blood*; (Epub Ahead of print), 2009.

AAML0523; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9800

Goldman SC, Lynch J, Harrison L, Gross TG, Shiramizu B, Sanger W, Perkins S, Cairo M. Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. *Blood*; (Epub Ahead of print), 2009.

ANHL01P1; Non-Hodgkin Lymphoma Committee; Abstract. COG # 9730

Gutierrez A, Grebliunaite R, Dahlberg S, Neuberg D, Zhang J, Sanda T, Protopopov A, Chin L, Winter SS, Larson RS, Kutok J, Silverman LB, Hunger S, Sallan SE, Look AT. Absence of T-cell receptor gene rearrangements predict induction failure in pediatric T-cell Acute Lymphoblastic Leukemia. *Blood*; (Epub Ahead of print), 2009.

9404; Acute Lymphoblastic Leukemia Disease Committee, Non-Hodgkin Lymphoma Committee; Abstract. COG # 9745

Bibliography Report

November 1st 2009 – November 30th 2009

Page 3 of 5

Heerema NA, Carroll AJ, Borowitz M, Devidas M, Larsen EC, Loh M, Mattano, Jr. LA, Maloney K, Raetz E, Wood BL, Winick N, Hunger S, Carroll WL. Amplification of AML1 does not impact early outcome of children with Acute Lymphoblastic Leukemia (ALL) treated with risk-directed chemotherapy: A report From the Children's Oncology Group (COG). *Blood*; (Epub Ahead of print), 2009. AALL0232, AALL0331, AALL03B1; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9753

Hogan L, Bhojwani D, Wang J, Morrison D, Yang JJ, Zhang Y, Zavadil J, Condos G, Hunger S, Willman CL, Relling MV, Raetz E, Carroll WL. Up-regulation of genes involved in folate metabolism characterize late but not early relapse in childhood Acute Lymphoblastic Leukemia. *Blood*; (Epub Ahead of print), 2009. AALL05B1; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9747

Hunger S, Mullighan C, Downing JR, Relling MV, Willman CL, Devidas M, Reaman GH, Carroll WL, Smith M, Zhang J, Gerhard D. The spectrum of mutations in childhood ALL. SIOF 2009 Award Session - Winner of SIOF Award for Basic Science. *Pediatr Blood Cancer*; 53(5):730, #O.065, 2009. 9906; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9819

Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom BC, Stork L, Neglia J. PMC Journal - In Process. Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia. [J Clin Oncol](#); (Epub ahead of print), 2009. ALTE02C2; Acute Lymphoblastic Leukemia Disease Committee, Cancer Control and Survivorship Scientific Committee; Research Paper. COG # 9596

Kutny M, Alonzo T, Gerbing R, Miller K, Ho PA, Heerema NA, Lange B, Gamis A, Meshinchi S. RUNX1 Mutations In Pediatric AML, A Report From The Children's Oncology Group. *Blood*; (Epub Ahead of print), 2009. 2941, 2961; Myeloid Disease Committee; Abstract. COG # 9741

London WB, Sondel P, Gilman AL, Ozkaynak F, Kreissman S, Buxton A, Chen AR, Matthay KK, Cohn S, Maris JM, Yu A. Success of Chimeric Anti-GD2 Antibody +GM-CSF+IL2 Immunotherapy in High-risk Neuroblastoma (NB) in First Response: a Critical appraisal. *Pediatr Blood Cancer*; 53(5):708, S.028, 2009. ANBL0032; Neuroblastoma Disease Committee; Abstract. COG # 9821

Matloub YH, Bostrom BC, Angiolillo A, Devidas M, Heerema NA, Gastier-Foster JM, Hunger S, Sather H, Linda SB, Carroll WL, Nachman J, Gaynon PS. Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or favorable chromosome trisomies are almost certain to be cured with graduated intensity therapy: Results of the CCG-1991 study. *Blood*; (Epub Ahead of print), 2009. 1991; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9746

Mullighan C, Collins-Underwood J, Phillips LA, Loudin M, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Mikhail F, Meyer J, Williams R, Cheng J, Carroll AJ, Heerema NA, Basso G, Pession A, Raimondi SC, Hunger S, Downing JR, Carroll WL, Rabin K. Rearrangement of CRLF2 in B-progenitor and Down syndrome associated Acute Lymphoblastic Leukemia. *Blood*; (Epub Ahead of print), 2009. AALL05B1; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9781

Mullighan C, Morin RD, Zhang J, Hirst M, Zhao Y, Yan CY, Finney R, Edmonson M, Su X, Buetow KE, Carroll WL, Chen I, Devidas M, Gerhard D, Harvey RC, Hu Y, Loh M, Reaman GH, Relling MV, Smith M, Downing JR, Hunger S, Willman CL, Marra MA. Next generation transcriptomic resequencing identifies novel genetic alterations in high-risk (HR) childhood acute lymphoblastic leukemia (ALL): A Report from the Children's Oncology Group (COG) HR ALL TARGET Project. *Blood*; (Epub Ahead of print), 2009. 9906; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9780

Bibliography Report

November 1st 2009 – November 30th 2009

Page 4 of 5

Myers K, Gerbing R, Alonzo T, Phillips C, Gamis A, Radloff GA, Perentesis J, Davies SM. Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia. *Blood*; (Epub Ahead of print), 2009.

2941, 2961; Myeloid Disease Committee; Abstract. COG # 9817

Nachman J, La MK, Hunger S, Heerema NA, Gaynon PS, Hastings C, Mattano, Jr. LA, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel N. *PMC Journal - In Process*. Young Adults With Acute Lymphoblastic Leukemia Have An Excellent Outcome with Chemotherapy Alone And Benefit From Intensive Post Induction Treatment: A Report From the Children's Oncology Group. [J Clin Oncol; 27\(31\):5189-5194, 2009.](#)

1961; Acute Lymphoblastic Leukemia Disease Committee, Cytogenetics Discipline Committee ; Research Paper. COG # 9398

Nagarajan R, Wiener A, Calaminus G. Quality of Life (QOL) Assessment of Patients Undergoing Therapy for Osteosarcoma in the EUROPEAN AMERICAN OSTEOSARCOMA STUDY (EURAMOS): Feasibility. *Pediatr Blood Cancer*; 53(5):799, PD.035, 2009.

AOST0331; Bone Sarcoma Disease Committee; Abstract. COG # 9787

Nelson M, Perkins S, Dave BJ, Coccia PF, Bridge JA, Lyden E, Heerema NA, Lones MA, Harrison L, Cairo M, Sanger W. *PMC Journal - In Process*. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Cancer Group study CCG-5961. [Br J Haematol; \(Epub ahead of print\), 2009.](#)

5961; Non-Hodgkin Lymphoma Committee; Research Paper. COG # 9565

O'Brien MM, Dahl G, Pounds S, Lacayo N, Taub J, Chang M, Weinstein H, Ravindranath Y, Campana D, Pui C, Rubnitz JE. Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. *Blood*; (Epub Ahead of print), 2009.

9421; Myeloid Disease Committee; Abstract. COG # 9816

Robb SL, Burns DS, Haase JE. Researchers and Clinicians Engaged in SMART Quality Assurance Monitoring. In *Pacific Melodies: Catching Waves to the Future*. Proceedings of the 2009 Conference of the American Music Therapy Association; 2009 Nov. 13-15; San Diego, CA:Research Poster, 2009.

ANUR0631; Nursing Discipline Committee; Abstract. COG # 9788

Robb SL, Docherty S, Haase JE. Ensuring Treatment Fidelity in a Multi-site Behavioral Intervention Study: Implementing NIH Behavior Change Consortium Recommendations in the SMART trial. In *Pacific Melodies: Catching Waves to the Future*. Proceedings of the 2009 Conference of the American Music Therapy Association; 2009 Nov. 13-15; San Diego, CA:Research Poster, 2009.

ANUR0631; Nursing Discipline Committee; Abstract. COG # 9774

Robinson B, Devidas M, Carroll AJ, Heerema NA, Willman CL, Hudome A, Woods EC, Ballantyne N, Reaman GH, Hilden JM, Camitta BM, Winick N, Carroll WL, Hunger S, Dreyer Z, Felix CA. Specific MLL partner genes in infant Acute Lymphoblastic Leukemia (ALL) associated with outcome are linked to age and white blood cell count (WBC) at diagnosis: A Report on the Children's Oncology Group (COG) P9407 Trial. *Blood*; (Epub Ahead of print), 2009.

P9407; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9779

Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg ME, Rutledge R, Burden L, Jorstad DT, Carroll AJ, Heerema NA, Winick N, Borowitz M, Hunger S, Carroll WL, Camitta BM. Improved Early Event-Free Survival with Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. [J Clin Oncol; 27\(31\):5175-5181, 2009. PMID: PMC2773475.](#)

AALL0031; Acute Lymphoblastic Leukemia Disease Committee, Cytogenetics Discipline Committee ; Research Paper. COG # 9396

Bibliography Report

November 1st 2009 – November 30th 2009

Page 5 of 5

Sredni ST, Gadd S, Huang C, Breslow N, Grundy PE, Green D, Dome JS, Shamberger RC, Beckwith B, Perlman EJ. Subsets of very low risk wilms tumor show distinctive gene expression, histologic, and clinical features. [Clin Cancer Res; 15\(22\):6800-6809, 2009](#). PMID: PMC2782600. 4941, AREN03B2; Renal Tumor Disease Committee; Research Paper. COG # 9810

Wagner LM, Perentesis J, Reid JM, Ames MM, Safgren SL, Nelson, Jr. MD, Ingle AM, Blaney S, Adamson P. Phase I Trial of two Schedules of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Children with Refractory Solid Tumors: a Children's Oncology Group Phase I Consortium Study. In: Proceedings of the Connective Tissue Oncology Society 15th Annual Meeting; 2009 Nov 5-7; Miami Beach, FL:85, #39349, 2009. ADVL0414; Developmental Therapeutics Scientific Committee; Abstract. COG # 9818

Walter R, Alonzo T, Gerbing R, Smith FO, Raimondi SC, Hirsch B, Gamis A, Franklin J, Hurwitz C, Loken MR, Meshinchi S. High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group. *Blood*; (Epub Ahead of print), 2009. AAML03P1; Myeloid Disease Committee; Abstract. COG # 9814

Weigel BJ, Lyden E, Tagen M, Hawkins D, Breitfeld PP, Meyer W, Anderson J, Stewart CF. Pharmacogenomic Association to Gastrointestinal Toxicities in Patients with High Risk Rhabdomyosarcoma treated with Vincristine and Irinotecan. In: Proceedings of the Connective Tissue Oncology Society 15th Annual Meeting; 2009 Nov 5-7; Miami Beach, FL:86, #39370, 2009. ARST0121, ARST0431; Bone Sarcoma Disease Committee; Abstract. COG # 9698

Wood BL, Winter SS, Dunsmore KP, Raetz E, Borowitz M, Devidas M, Winick N, Carroll WL, Hunger S, Loh M. Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction—A Children's Oncology Group (COG) Study. *Blood*; (Epub Ahead of print), 2009. AALL03B1, AALL0434; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9778

Zhang J, Mullighan C, Harvey RC, Buetow KE, Carroll WL, Chen I, Devidas M, Edmonson M, Gerhard D, Hu Y, Loh M, Phillips LA, Reaman GH, Relling MV, Smith M, Downing JR, Willman CL, Hunger S. Mutations in the RAS signaling, B-Cell development, TP53/RB1, and JAK signaling pathways are common in High Risk B-precursor Childhood Acute Lymphoblastic Leukemia (ALL): A report from the Children's Oncology Group (COG) high-risk (HR) ALL TARGET project. *Blood*; (Epub Ahead of print), 2009. 9906; Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9744